EVGN Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

0.544

Open

0.540

VWAP

0.52

Vol

202.33K

Mkt Cap

6.72M

Low

0.510

Amount

105.57K

EV/EBITDA(TTM)

--

Total Shares

12.10M

EV

4.35M

EV/OCF(TTM)

--

P/S(TTM)

2.59

Evogene Ltd is an Israel-based company, engaged in leveraging computational biology to design products for life-science-based industries including human health, agriculture, and industrial applications. Leveraging Big Data and Artificial Intelligence while incorporating a deep understanding of biology, Evogene established its technology, the Computational Predictive Biology (CPB) platform, to computationally design microbes, small molecules and genes as the core components for life-science products. Evogene holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production.

Show More

Events Timeline

(ET)

2026-06-02

07:10:00

Evogene Completes First-in-Human Phase 1 Study of BMC128

2026-05-20 (ET)

2026-05-20

07:10:00

Evogene Reports Q1 Revenue of $300,000, Down from $2.3M Last Year

2026-04-02 (ET)

2026-04-02

16:10:00

Evogene Receives Nasdaq Compliance Notice

2026-03-26 (ET)

2026-03-26

16:40:00

Evogene Files to Sell 5.08M Ordinary Shares

2026-03-05 (ET)

2026-03-05

07:10:00

Evogene Reports Q4 Revenue of $314M

2026-02-17 (ET)

2026-02-17

08:10:00

Evogene Partners with QUT to Develop Novel Cancer Drugs

2026-02-11 (ET)

2026-02-11

08:10:00

Evogene Collaborates with Systasy to Develop New Therapies

News

PRnewswire

06-09PRnewswire

Evogene to Showcase New Technologies at BIO International Convention

Yahoo Finance

06-06Yahoo Finance

EverGen Infrastructure Reports Strong Q1 2026 Earnings Growth

PRnewswire

06-02PRnewswire

Evogene's BMC128 Phase 1 Clinical Trial Shows Promising Results

PRnewswire

05-20PRnewswire

Evogene Reports Q1 2026 Financial Results and Strategic Developments

seekingalpha

05-20seekingalpha

Evogene Reports Q1 Earnings Miss with Significant Revenue Decline

seekingalpha

05-19seekingalpha

Evogene to Announce Q1 Earnings on May 20

1 Analyst Rating

Wall Street analysts forecast EVGN stock price to rise

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

2.50

Averages

2.50

High

2.50

Current: 0.000

Low

2.50

Averages

2.50

High

2.50

Alliance Global

Buy

maintain

AI Analysis

2026-05-26

Reason

Alliance Global

Price Target

AI Analysis

2026-05-26

maintain

Buy

Reason

Alliance Global lowered the firm's price target on Evogene (EVGN) to $2.15 from $2.25 and keeps a Buy rating on the shares. Evogene reported Q1 results that were within the range off expectations, with the main points behind the company's focus on the ChemPass AI discovery engine, the discontinuation of the Bayer (BAYRY) partnership, and a cash balance that appears to extend into 2H27, the analyst tells investors in a research note. The firm said the lower price target is due to the Bayer partnership discontinuation.

Alliance Global

Scott Henry

Buy

maintain

2026-04-13

Reason

Alliance Global

Scott Henry

Price Target

2026-04-13

maintain

Buy

Reason

Alliance Global analyst Scott Henry raised the firm's price target on Evogene to $2.25 from $1.75 and keeps a Buy rating on the shares. The company has pivoted its model to focus on its ChemPass AI engine for designing small molecules for the pharmaceutical and agricultural industries, the analyst tells investors in a research note. The firm sees Evogene signing 10 partnerships by early 2027.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for EVGN

Unlock Now

Valuation Metrics

The current forward P/E ratio for Evogene Ltd (EVGN.O) is 0.00, compared to its 5-year average forward P/E of -1.49. For a more detailed relative valuation and DCF analysis to assess Evogene Ltd's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-1.49

Current PE

0.00

Overvalued PE

-0.52

Undervalued PE

-2.46

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

-0.61

Current EV/EBITDA

-0.01

Overvalued EV/EBITDA

0.13

Undervalued EV/EBITDA

-1.36

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

N/A

5Y Average PS

17.10

Current PS

2.63

Overvalued PS

57.15

Undervalued PS

-22.95

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

yea US penny stocks

Intellectia · 16 candidates

Price: $0.10 - $5.00Volume: >= 300,000Rsi Category: moderate, overboughtPrice Change Pct: $0.00 - $15.00Relative Vol: >= 1.50List Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20, PriceAboveMA200Macd: positive, bullish

Ticker

Name

Market Cap$

Apyx Medical Inc

166.48M

Captivision Inc

19.92M

Aptorum Group Ltd

9.85M

RenovoRx Inc

40.68M

TRON Inc

622.85M

Cardlytics Inc

50.19M

stocks under $2 for day trade today

Intellectia · 158 candidates

Price: <= $2.00Volume: >= 500,000Price Change Pct: $-5.00 - $20.00Relative Vol: >= 1.50List Exchange: XNYS, XNAS, XASE

Ticker

Name

Market Cap$

Phio Pharmaceuticals Corp

12.06M

Plug Power Inc

2.84B

NUBURU Inc

56.42M

Tian Ruixiang Holdings Ltd

10.04M

Jet.AI Inc

5.61M

Bit Digital Inc

563.19M

stocks between $1.00 and $1.10

Intellectia · 54 candidates

Price: $1.00 - $1.10

Ticker

Name

Market Cap$

Adagio Medical Holdings Inc

22.87M

Heidmar Maritime Holdings Corp

61.90M

CCSC Technology International Holdings Ltd

4.15M

Auddia Inc

3.35M

Estrella Immunopharma Inc

42.45M

CytoMed Therapeutics Ltd

11.15M

Whales Holding EVGN

Trading Trends

People Also Watch

Frequently Asked Questions

What is Evogene Ltd (EVGN) stock price today?

The current price of EVGN is 0.5103 USD — it has decreased -8.11

What is Evogene Ltd (EVGN)'s business?

Evogene Ltd is an Israel-based company, engaged in leveraging computational biology to design products for life-science-based industries including human health, agriculture, and industrial applications. Leveraging Big Data and Artificial Intelligence while incorporating a deep understanding of biology, Evogene established its technology, the Computational Predictive Biology (CPB) platform, to computationally design microbes, small molecules and genes as the core components for life-science products. Evogene holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production.

What is the price predicton of EVGN Stock?

Wall Street analysts forecast EVGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EVGN is2.50 USD with a low forecast of 2.50 USD and a high forecast of 2.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Evogene Ltd (EVGN)'s revenue for the last quarter?

Evogene Ltd revenue for the last quarter amounts to 334.00K USD, decreased -85.74

What is Evogene Ltd (EVGN)'s earnings per share (EPS) for the last quarter?

Evogene Ltd. EPS for the last quarter amounts to -0.60 USD, increased 57.89

How many employees does Evogene Ltd (EVGN). have?

Evogene Ltd (EVGN) has 142 emplpoyees as of June 18 2026.

What is Evogene Ltd (EVGN) market cap?

Today EVGN has the market capitalization of 6.72M USD.